Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761215 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections
A Phase 2 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT00761215 is a Phase 2 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 192 participants.
The verdict
NCT00761215, a Phase 2 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.
Interventions
- DRUG TR-701 200 mg
- DRUG TR-701 300 mg
- DRUG TR-701 400 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2008-09-17 |
| Est. Completion | 2009-02-24 |
| Phase | Phase 2 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00761215
The ClinicalTrials.gov registry entry for NCT00761215 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which TR-701 200 mg is the first listed.
NCT00761215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00761215 about?
NCT00761215 is a clinical study titled "Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections". The purpose of the study is to determine the oral dosage of TR-701 to be used in Phase III studies in patients with complicated skin and skin structure infections.
What is the current status of trial NCT00761215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2008-09-17. Estimated completion is 2009-02-24.
What interventions are being tested in trial NCT00761215?
The interventions under investigation include: TR-701 200 mg (DRUG), TR-701 300 mg (DRUG), TR-701 400 mg (DRUG).
Who is sponsoring clinical trial NCT00761215?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.